Morning Alert: Intel Corporation (NASDAQ:INTC), MannKind (NASDAQ:MNKD), Microsoft (NASDAQ:MSFT), Southwest Bancorp Inc. (NASDAQ:OKSB), Green Plains Inc. (NASDAQ:GPRE)

Intel Corporation (INTC) has announced its modem that is integrated with a power amplifier to provide 3G network speeds to devices. The size of the modem is approximately 300 square millimeters, potentially the smallest modem-chip in the world. Called the XMM 6255, Intel targets the modem at the Internet of Things devices, for use in fields like healthcare and technology. Intel Corporation (NASDAQ:INTC) belongs to Technology … Continue reading Morning Alert: Intel Corporation (NASDAQ:INTC), MannKind (NASDAQ:MNKD), Microsoft (NASDAQ:MSFT), Southwest Bancorp Inc. (NASDAQ:OKSB), Green Plains Inc. (NASDAQ:GPRE)

Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

On August 11,2014 MannKind Corp. (NASDAQ:MNKD) reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of $30.5 million. MannKind Corp. (NASDAQ:MNKD) belongs to Healthcare sector. Its … Continue reading Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

Hot Stocks : MannKind Corp. (NASDAQ:MNKD), NCR Corp. (NYSE:NCR), PriceSmart Inc. (NASDAQ:PSMT), Alliance Fiber Optic Products Inc. (NASDAQ:AFOP), NVR, Inc. (NYSE:NVR)

MannKind Corporation (NASDAQ:MNKD) signed a $925 million worldwide licensing agreement with Sanofi SA (ADR) (NYSE:SNY) (EPA:SAN) on August 11. The French drugmaker already has five principal products in diabetes. However, its top-selling diabetes drug Lantus will lose patent protection next year. Lantus is sold in more than 120 countries, generating $7.6 billion in annual revenue. MannKind Corp. (NASDAQ:MNKD) belongs to Healthcare sector. Its weekly performance … Continue reading Hot Stocks : MannKind Corp. (NASDAQ:MNKD), NCR Corp. (NYSE:NCR), PriceSmart Inc. (NASDAQ:PSMT), Alliance Fiber Optic Products Inc. (NASDAQ:AFOP), NVR, Inc. (NYSE:NVR)

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN) insider ownership is 0.10%. Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical … Continue reading Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences GILD NASDAQ:GILD

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session and finished the day at $65.48. Traded volume was 43.15million … Continue reading Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)